Terms ending in 2036
Every in-force patent on Pharmacyclics, Inc.'s record whose computed term ends in 2036, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,655,857 | Pharmaceutical Formulations of a Bruton's Tyrosine Kinase Inhibitor In force · High confidence | Pharmacyclics LLC | In force | High confidence | |
| US 10,010,507 | Pharmaceutical Formulations of a Bruton's Tyrosine Kinase Inhibitor In force · Medium confidence | Pharmacyclics LLC | In force | Medium confidence | |
| US 10,213,386 | Pharmaceutical Formulations of a Bruton's Tyrosine Kinase Inhibitor In force · Low confidence | Pharmacyclics LLC | In force | Low confidence | |
| US 10,828,259 | Pharmaceutical Formulations of a Bruton's Tyrosine Kinase Inhibitor In force · Low confidence | Pharmacyclics LLC | In force | Low confidence | |
| US 12,551,448 | Pharmaceutical Formulations of a Bruton's Tyrosine Kinase Inhibitor In force · Low confidence | Pharmacyclics LLC | In force | Low confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.